ImmunityBio (IBRX) Fundamentals 2026 — Revenue Analysis | SniperIQ
ImmunityBio (IBRX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $8.0B, trading at $7.63 on the NASDAQ. This SniperIQ fundamentals page covers ImmunityBio's valuation, profitability (net margin -606.2%), revenue (
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ImmunityBio's market cap?
ImmunityBio (IBRX) has a market capitalization of approximately $8.0B, trading at $7.63 on the NASDAQ. Market cap moves with the live share price.
How profitable is ImmunityBio?
ImmunityBio runs a net profit margin of -606.2%, a gross margin of 93.8%, and an operating margin of -185.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ImmunityBio generate?
ImmunityBio reported revenue of
Does ImmunityBio pay a dividend?
ImmunityBio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ImmunityBio financially healthy?
ImmunityBio carries a debt-to-equity ratio of -1.29x and a current ratio of 6.67x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ImmunityBio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ImmunityBio (IBRX) the key facts are: market cap $8.0B, revenue
Track ImmunityBio's full fundamentals live
Get ImmunityBio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.